|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Synthetic PPARγ ligands can be used for treatment of intrahepatic cholestasis and cholestasis-associated dyslipidemia potentially.
|
31658492 |
2020 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Though, PPAR- γ full agonists such as Thiazolidinediones (TZDs) are well established agents for dyslipidemia and type 2 diabetes mellitus (T2D), the side effect profile associated with TZDs has potentiated an imminent need to come up with newer agents that act through this pathway.
|
31333088 |
2019 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
|
31364797 |
2019 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Synthetic PPAR ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists) while a new generation of dual agonists reveals hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action.
|
31161987 |
2019 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Modulation of hyperglycemia and dyslipidemia in experimental type 2 diabetes by gallic acid and p-coumaric acid: The role of adipocytokines and PPARγ.
|
30021345 |
2018 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings provide insights into the cytoprotective effects of RSG on Sertoli cells and suggest that PPARγ activation may be a useful therapeutic method for the treatment of Sertoli cell dysfunction caused by dyslipidemia.
|
30333041 |
2018 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study aimed to investigate the analgesic effect and the probable mechanism of Gentiopicroside on Diabetic Peripheral Neuropathy (DPN), and to figure out the association among Gentiopicroside, dyslipidemia and PPAR- γ/AMPK/ACC signaling pathway.
|
30308492 |
2018 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
GQ-177 acts as a partial PPARγ agonist that improves obesity-associated insulin resistance and dyslipidemia with atheroprotective effects in LDLr(-/-) mice.
|
26706782 |
2016 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We investigated the association of PPAR-γ C1431T-polymorphism with CAD and dyslipidaemia in 787 individuals.
|
25896411 |
2015 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, CYP2J2 expression upregulated PPARγ, which has been shown to induce adipogenesis, which attenuates dyslipidemias observed in diabetes.
|
25389363 |
2015 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The objective was to investigate the associations of the PPAR α and PPAR γ polymorphisms with dyslipidemia.
|
24460649 |
2014 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion these results suggest that PPARγ gene variability may increase the risk of dyslipidemia.
|
25216344 |
2014 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Monascin improves diabetes and dyslipidemia by regulating PPARγ and inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice.
|
23673903 |
2013 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This is the first PPARG germline mutation associated with dyslipidemia and colonic polyp formation that can progress to full-blown adenocarcinoma.
|
20123124 |
2010 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias.
|
18388689 |
2008 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PPARG mutations may cause insulin resistance and dyslipidemia, but little is known about the mechanisms of the abnormalities of lipid metabolism.
|
18713822 |
2008 |
|
Dyslipidemias
|
0.400 |
Therapeutic
|
group |
CTD_human |
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
|
16168052 |
2005 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The peroxisome proliferator-activated receptor-gamma (PPARgammas) are also regulators of adipocyte differentiation, and the PPARgamma-2 gene could also contribute to the development of dyslipidemia.
|
12974743 |
2003 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator activated receptor-gamma is an important factor in adipocyte differentiation and energy metabolism and is thus a candidate gene for obesity, insulin resistance and dyslipidaemia.
|
12406034 |
2002 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Pro(12)Ala (P12A) variant of exon B of the peroxisome proliferator-activated receptor gamma(2) (PPAR gamma) been variably associated with obesity, insulin sensitivity, diabetes, and dyslipidemia, but its role in insulin resistance-associated traits remains uncertain.
|
11158005 |
2001 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia.
|
10924736 |
2000 |